molecular biology cell Articles
-
Development of Gene Therapy Viral Vectors for Rare Diseases
In many cases, gene therapy requires a vector to deliver the gene therapy drug to the target cell. Viral vectors have been one of the most widely studied vectors due to their outstanding transduction efficiency and other significant advantages. Viral vector-based gene therapy has now achieved good clinical results. More than a dozen viral gene therapy products have been approved for the treatment ...
By Protheragen
-
The Medical University of South Carolina - Case study
Medical University of South Carolina (MUSC) is South Carolina’s only comprehensive academic health science center. Its purpose is to preserve and optimize human life in South Carolina through the vision to lead health innovation for the lives it touches. Ludivine Renaud has a Bachelor’s degree in marine biology from the College of Charleston, a Master’s degree in environmental ...
-
Molecular analysis of vibrio cholerae o1, o139, non-o1, and non-o139 strains: clonal relationships between clinical and environmental isolates
Rajiv Gandhi Centre for Biotechnology, Jagathy, Thiruvananthapuram 695 014, India; Center for Marine Biotechnology, University of Maryland Biotechnology Institute, Baltimore, Maryland 212022; Department of Cell and Molecular Biology, University of Maryland, College Park, Maryland 207426; School of Public Health, University of São Paulo, São Paulo, SP, 01246-904, São Paulo, Brazil; Department of ...
-
Aelan Cell Technologies Adds Human Embryonic Stem Cell Expert Meenakshi Gaur, Ph.D. to Stem Cell Clinical Program
SAN FRANCISCO, CA--(Marketwired - Sep 11, 2015) - Aelan Cell Technologies announced today the addition of Meenakshi Gaur, Ph.D. to their stem cell clinical program. Dr. Gaur will serve as the Director of Research and Development of the Stem Cell Program, leading a research team that will develop technology aimed at rejuvenation of human mesenchymal stem cells for clinical applications. "Dr. Gaur ...
-
The Spark for Decoding Biology: An Origin Story
Recursion is entering an exciting period in our evolution as a clinical-stage biotechnology company. We recently announced that we’ve enrolled the first patient in the first human efficacy trial in our company’s history — a significant milestone for us, and for the patients we hope to serve. Our Phase 2 trial is investigating the treatment of a disease called cerebral ...
By Recursion
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you